Abstracts of ICI 2016 International Congress of Immunology, 21–26 August 2016, Melbourne, Australia

Abstract

The restoration of defects of immune and interferon systems in immunocompromised children suffering from recurrent viral and viral-bacterial infections is the actual problem. We studied 3 groups of immunocompromised children 5-8 years suffering from recurrent respiratory infections. Group I included 13 children with recurrent acute respiratory viral infections(ARVI), group II - 14 children with recurrent ARVI, group III - 20 children with recurrent ARVI and chronic bacterial infections of upper respiratory tract(URT). Mono- or mixt herpes viral infections were detected in all groups. Immune and interferon (IFN) systems were investigated: T-, B-chains, NK, neutrophilic granulocytes(NG), serum IFNα and IFNγ. Immunodeficiencies(ID) with the predominant defects of NG and IFNs were identified. 3 different programs of IFN- and immunotherapy were created: in group I local and system therapy recombinant IFNα2(viferon) was used; in group II IFN therapy and for correction of defects of NG - glyukozoaminilmuramildipeptid (likopid) were used; in group III - IFN therapy and for the correction of of humoral immunity - IRS-19 were used; in children of all 3 groups inosine pranobex was used for elimination of herpesviruses. The study demonstrated: reducing the frequency of ARVI in 3,2 (group I), in 5,8 times (group II), exacerbations of chronic diseases of URT in 4 times, increasing the period of “days free from diseases” from 7-10 to 100-150 days. IFN restored levels of IFNα in all groups. Likopid corrected defects of NG in group II, IRS-19 restored the humoral immunity in group III. Created programs shown high clinical and immunological efficiencies.